b'Health Equity CornerInequities in cancer care and outcomes are evident in every aspectTipirneni and Dr. John Scott are the M-SHIELD Co-Directors and are of cancer care for racial and ethnic minority groups, for peoplebuilding their team now. with lower socioeconomic position, for people in rural areas, forTo learn more about cancer health disparities, we recommend the older people and for young adults, and for immigrants, sexual andfollowing resources: gender minorities, and people with low health literacy.MOQC, including the Coordinating Center, participating practices,National Cancer Institute (NCI) Center to Reduce Cancerand Patient and Caregiver Oncology Quality Council (POQC), isHealth Disparities (CRCHD) committed to centering health equity as one of our four strategicAmerican Society of Clinical Oncology Equity in Cancerinitiatives. We are considering equity in selection of our measuresCare & Research and our quality improvement initiatives. To accelerate this work,Centers for Medicare & Medicaid Services (CMS) Office ofwe will be forming an Equity Task Force. Please let us know if youMinority Health are interested in participating. Michigan Office of Equity and Minority Health (OEMH)We are also excited to share that Blue Cross Blue Shield ofContact moqc@moqc.org if you have ideas for addressing Michigan (BCBSM) is doing the same with the launch of a newinequities in cancer care that youd like to see MOQC support or if Collaborative Quality Initiative (QQI), Michigan Social Healthyoure interested in participating in the Equity Task Force.Interventions to Eliminate Disparities (M-SHIELD). Dr. Renu MOQC Measures 2021MEDICALONCOLOGYMEASURESVBR MEASUREChemotherapy intent (curative vs. non-curative) documented before or within 2 weeks after administration Oral chemotherapy monitored and addressed on visit/contact following start of therapy Tobacco cessation counseling administered or patient referred in past year NK1RA & olanzapine prescribed or administered with high emetic risk chemotherapyXNK1RA or olanzapine administered with first cycle low/moderate emetic risk (lower is better)XComplete family history documented in patients with invasive cancer G-CSF administered to patients who received chemotherapy with non-curative intent (lower is better) Hospice enrollmentXHospice enrollment & enrollment within 7 days of death (lower is better)XChemotherapy administered within the last 2 weeks of life (lower is better)Percentage of patients who died from cancer with more than one emergency department visit in the last 30 days of life (lower is better) Hospice enrollment or documented discussion Advanced imaging within 60 days of diagnosis for patients with Stages III breast cancer 1Bone-modifying agent given to patients with bone metastases from breast cancer or multiple myeloma 1Growth factor used in patients receiving chemotherapy in the non-curative setting (lower is better)GYNONCOLOGYMEASURESVBR MEASURETobacco cessation counseling administered or patient referred in past year NK1RA & olanzapine prescribed or administered with high emetic risk chemotherapy NK1RA or olanzapine administered with first cycle low/moderate emetic risk (lower is better) Complete family history documented in patients with invasive cancer G-CSF administered to patients who received chemotherapy with non-curative intent (lower is better) Hospice enrollment Hospice enrollment & enrollment within 7 days of death (lower is better) Chemotherapy administered within the last 2 weeks of life (lower is better) Operative report with documentation of residual disease within 48 hours of cytoreduction for women with invasive ovarian, Xfallopian tube, or primary peritoneal cancer Platin or taxane administered within 28 days following cytoreduction to women with invasive Stage I (grade 3), IC-IV ovarian, Xfallopian tube, or primary peritoneal cancer 7'